Details provided are based upon best-known information made available to MedBud, please reconfirm with your pharmacy. This product was last updated: MedBud typically only updates products when availability changes, or new information is provided. An availability status from several months ago can still be valid when a product remains in/out of stock, or has been discontinued.
Dosing Look-Up Table (Estimated)
Please note values above are based on registered THC/CBD percentages, subject to ±10% allowed variance. Values provided are 'best case', losses to air during vaporisation or combustion will always occur.
L.A. Amnesia combines the genetics of the world famous Dutch strain, Amnesia Haze, with a highly potent Kush variety.
Dutch Bred, American Genetics
L.A. Amnesia is a potent, high yield sativa with a revved up THC count and is the result of a collaboration between the legendary growers of Paradise Seeds and legendary cannasseur, Tommy Chong.
We were looking for a very special sativa to bring to the exclusive Tommy Chong’s™ line and this is definitely it. L.A. Amnesia combines the genetics of the world famous Dutch strain, Amnesia Haze, with a highly potent Kush variety. Named after Los Angeles, this heavenly strain is a perfect match for the City of Angels!
Information provided could come from a third-party source, and likely does not accurately reflect characteristics of the medication we're associating it with - we primarily provide these descriptions for those interested in strain lineage and history, which could also be inaccurate. Any information which could be taken as medical advice should be strictly disregarded. Please consult your doctor regarding the suitability of medications for your condition(s).
About Lyphe Group Ltd
From Lyphe Group, a range of medical flowers and oils focused on giving doctors reassurance in the efficiency and consistency of our supply chain, while providing quality pharmaceutical-grade medication.
At Lyphe our vertical operations span product manufacturing, clinical care, pharmacy dispensing and doctor education. Our direct-to-patient and technology-led approach has quickly established us as the market’s largest player, with a 30% share of all patients. We have also recently entered the Australian market, where we intend to replicate our model of success.